Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 529

Next Previous
Drug Profile

IMM 529

Alternative Names: IMM-529

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immuron
  • Class Anti-infectives; Polyclonal antibodies
  • Mechanism of Action Clostridium difficile toxB protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Clostridium difficile infections

Most Recent Events

  • 30 May 2025 Immuron announces intention to submit IND application to US FDA for IMM-529 in Clostridium difficile infections in August 2025
  • 05 Sep 2024 Immuron completes pre-IND meeting with US FDA on the development of IMM 529 to prevent or treat Clostridioides difficile infections
  • 02 Jul 2024 Immuron plans a phase II trial for Clostridium difficile infections in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top